New shipCVS Health $CVS
Grew revenue 7.8% in FY2025 to $402.1 billion, operating margin 1.2% against a 0.6% median for drug stores and proprietary stores, equity 29.7% of assets.
Last filing8-K · Item 5.02 Departure or Election of Directors; Appointment of Officers, 17 Aug 2026
Edgarette’s full reading · exposure, experience, soundness, credibility, range
🫧 Edgar looked up CVS HEALTH CORPORATION ($CVS). Last filing: 8-K (5.02 Departure or Election of Directors; Appointment of Officers), 2026-08-17. 8 event filings (8-K) in the past twelve months.
🔖 Exposure: revenue $402.1B (FY2025), total debt $64.6B. Experience: revenue up 7.8% on the year, up 8.3% a year over 4 years; operating margin 1.2%, down from 2.3%. Soundness: equity 29.7% of assets, return on equity 2.4%, payout 192.1% of profit. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $390.9B and $449.4B next year (method v4.1: its own 4-year record of growth weighed at 50% against $10B+ filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $367.7B to $475.2B. A statistical range, not company guidance. Against peers (57 filers, $50M+ revenue, its industry group): operating margin 1.2% against a 0.6% median; growth 7.8% against 4.1%.
Read from its own SEC filings · nothing written, nothing inferred
Gold paid out, navy kept. Kept share × return on equity = the growth it can fund itself. Facts from the filings, not a recommendation.
Speed and cash · fiscal 2025
Both views must agree for a label · a description, not advice.
| Cash flow (op · inv · fin · free) | $10.6B · −$5.9B · −$4.9B · $7.8B |
| Investment book (cash · short · long) | $8.5B · $817M · $19.9B · current ratio 0.84 · unrealized $118M |
| Revenue swing · equity of assets | 2.9% · 29.7% |
Cvs Health is growing faster than its size class, with steadier revenue. Its own audited SEC figures.
The figures, as filed
| Fiscal year end | 2025-12-31 |
| Revenue | $402.1B |
| Revenue, on the year | 7.8% |
| Revenue, a year over the record | 8.3% |
| Operating margin | 1.2% |
| Operating margin, prior year | 2.3% |
| Net margin | 0.4% |
| Research and development | not filed separately |
| Total debt | $64.6B |
| Equity of assets | 29.7% |
| Return on equity | 2.4% |
| Payout of profit | 192.1% |
| Dividend per share | $2.66 |
| Earnings per share | $1.4 |
| Book value per share | $59.18 |
| Revenue per share | $316.34 |
| Shares outstanding | 1,271,000,000 |
| Audited years read | 5 |
Peers: the median of 57 filers with $50M+ revenue in retail-drug stores and proprietary stores.
Classic signals · fiscal 2025Altman Z″ 0.99 distress zone 1968Piotroski F 7 of 9 solid 2000Beneish M not enough filed detail (needs receivables, cost of revenue, PP&E, depreciation, SG&A for two years)Sloan accruals -3.5% earnings backed by cash 1996DuPont ROE 2.3% = margin 0.4% × turns 1.59 × leverage 3.36
What a terminal subscription used to buy, a filing and arithmetic now give anyone. Published method, from the same filings. Display only: nothing here moves the range or its receipt. Why? →
Health HarborCvs Health sails as: New ship
Health watch · 12 monthsDirector or officer change ×3
Sailing speed follows growth: 7.6% a year crosses the harbor in 57 seconds.
🌊 Visit the Bay →No warning signs on the measures below.
Boat condition = number of warning signs: a serious warning filing in 12 months; liabilities over assets; slow and jumpy; negative operating cash; an operating loss; negative free cash flow outside regulated utilities; an 80% revenue range of ±25% or wider. A picture of the signs, not a rating and not investment advice.
Brand success factors · calendar 2025
The Trillion Score: 605
Exponential Success Score
Built on over $200 trillion of sworn revenue, 13 years of data, 770,002 figures. Sealed by Edgarette.
How The Trillion Score works. We read eight measures of success from CVS Health's own SEC filings and test each one against the public companies in its field, here drug stores and proprietary stores. The longer and fuller the record, the more weight those results carry. A model built on past filings then turns them into the odds of thriving, which means outgrowing the field for three years without a severe decline. A score of 500 is about average, and every 100 points doubles the odds. Every company is ranked on this same scale.
What it says here. At 605, CVS Health's odds of thriving come to 54%, against about 37% for the typical filer. It meets 6 of 6 success points.
What the score means
The higher the score, the more often companies went on to thrive. At this level, about 57 of every 100 did.
Share of companies that beat their field for three years with no severe decline, tested on 2019 to 2022 filings.
Fall Risk: Low
Separate from the score, this asks what could go wrong: the odds of sales falling 30% or the filings stopping within three years. In the tests, about 7 of every 100 companies in the Low band did. That is the group's history, not a forecast for this company.
| Money | It keeps about 2 cents of free cash from each sales dollar after paying for its plants and equipment. | low |
| Swings | Even in its worst years on record, sales still grew. | 4.1% a year |
| Filed events | No such 8-K events in the last two years. | 0 |
The eight success points
| Point | What it means | Place in field | |
|---|---|---|---|
| Speed | Sales grew faster than most of its field. | 100 of 100 | Met |
| Steadiness | Growth was strong for how much it swung, so it looks dependable. | 100 of 100 | Met |
| Price premium | It keeps more of each sales dollar than most of its field. | 100 of 100 | Met |
| Margin stays above the field | Its margin has held above the field year after year. | 67 of 100 | Met |
| Moat half-life | Its margin edge is fading slowly, if at all. | 67 of 100 | Met |
| Brand spend yield | Not filed. | ||
| Learning curve | Costs fell as a share of sales as it grew. | 100 of 100 | Met |
| Climb in the field | Not filed. | ||
The actuarial view
| Credibility | With 8 years of filings, the record earns 52% of the weight. The rest stays at the middle of the field. | 0.52 |
| Severe decline, class A | About 22 of every 100 companies with this many points fell 30% or stopped reporting within three years. | 21.8% |
| Actual vs expected | Sales are 40% higher than if it had simply kept pace with its field. | 1.40 |
Top of its field: #1 CVS Health · #2 Petmed Express · #3 111 · #4 Ridgetech
Ranked by The Trillion Score. See the method and score your own brand. Tested on 2019 to 2022 filings. Odds, class and Fall Risk figures are the experience of similar filers, not a forecast for this company. A statistical description of past filings, not a rating or advice.
- 8-K · 2026-08-17 · 5.02 Departure or Election of Directors; Appointment of Officers; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits
- 10-Q · 2026-08-05
- 8-K · 2026-08-05 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits
- 8-K · 2026-05-18 · 5.02 Departure or Election of Directors; Appointment of Officers; 5.07 Submission of Matters to a Vote of Security Holders
- 10-Q · 2026-05-06
- 8-K · 2026-05-06 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits
Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price. Reporting, not investment advice. No price targets and no trading recommendations. Figures from the SEC’s own data · every filing · this page as JSON · ask about another company